Program Grants

Active:

  • National Institute of General Medical Sciences Grant (PI: Thomas E) $2,000,000. 9/10/2017-8/31/2022. A Multifaceted Approach to Study Tissue and Cell Type Specific Molecular Mechanisms of the Host Response to Acute/Chronic Viral Infection. Funds provided to support clinical research with emphasis on the innate immune responses of primary epithelial cells from several organs to chronic viral infections.
  • Bankhead-Coley Florida Clinical Cancer Research Grant (PI: Thomas E) $1,866,436 (with indirect costs). 3/1/2017-2/28/2022. Identifying Infection and Molecular Determinants of Health Disparities in HCV Infected Minority Populations for the Prevention of HCC.  Funds provided to develop a predictive model to aid in the detection of high risk subgroups and increase the early detection of HCC.

Pending & Recent Submissions:

  • SCCC Tissue Bank Support Grant (PI: Thomas E, 5% Effort) $20,000 (no indirect costs). 1/1/2014-1/1/2015. Money would be provided for supplies to bank 100 Hepatocellular Carcinoma Specimens.

Completed:

  • NIH Diversity Supplement FY2014-2016 (PI: Thomas E, Mentee-Danielle Turnquest) $138,000 ($50,000 indirect costs). 6/1/2014-6/1/2016. Modeling the Response in Hepatocytes and Kupffer Cells to HIV/HCV Coinfection. This is a diversity supplement to support the training of Danielle Turnquest on a research project focused on HIV/HCV coinfection. Awarded 6/1/14.
  • Howard Hughes Medical Institute Undergraduate/High School Scholars Research Program. (PI: Thomas E, 2% Effort) $1,800 (no indirect costs). Summer 2014. Funds to support Zachery Austin, Danielle Turnquest, Miguel Montana, Katrina Montane and Paolo Scalla, summer students, in my laboratory for a summer rotation focused on studying the antiviral response in hepatocytes.
  • CFAR Developmental Grant (PI: Thomas E, 10% Effort) $40,000 (no indirect costs). 1/1/2014-1/1/2016. Identification of HIV/HCV Coinfected Patients in South Florida for the prevention of Hepatocellular Carcinoma. Money is provided to establish and study a clinical cohort of HIV/HCV coinfected patients to complement the ongoing laboratory program. Awarded 12/13/13.
  • Jay Weiss SCCC Health Disparity Grant (PI: Thomas E) $75,000 (no indirect costs). 1/1/2014-1/1/2015. Assessing HCV Related Health Disparities Through Screening and Linkage to Care. Money is provided to establish and study a clinical cohort of HCV infected patients to complement the ongoing laboratory program.
  • CFAR Administrative Supplement in HIV/AIDS-FY2013 (PI: Thomas E, 15% Effort) $153,000 ($53,000 indirect costs). 8/1/2013-8/1/2014. Modeling the Response in Hepatocytes and Kupffer Cells to HIV/HCV Coinfection. This is an administrative supplement to the parent Miami-CFAR grant to support the initiation of a project on HIV/HCV coinfection.
  • NIDA/NHSN R25 Early Career Stage Mentoring Program (PI: Thomas E, 5% Effort) $15,000 (no indirect costs). 7/18/2013-8/1/2016. Assessing Infection Prevalence and Molecular Determinants of Health Disparities in Hepatitis C Virus Infected African Americans, Hispanics and Haitian Communities that have a High Incidence of IV Drug Use in South Florida. This is a subcontract from the R25 program to develop a grant on HCV infection that will be submitted to NIDA within one year. Funds are to support grant development and provide funds for pilot studies.
  • Schiff Center for Liver Diseases Award (PI: Thomas E, 5% Effort) $80,000 (no indirect costs). 6/1/2013-5/31/2017. Funds provided to support clinical research carried out through the Center for Liver Diseases on viral hepatitis.
  • Stanley J. Glaser Award (PI: Thomas E, 5% Effort) $40,000 (no indirect costs). 6/1/2013-5/31/2014. Elucidation and Application of the Mechanisms of Action of Ribavirin and Interferon in HCV Antiviral Therapy. This project involves studies on the mechanisms of action of antiviral agents used to treat HCV infection.
  • University of Miami Institutional Start Up Funds (PI: Thomas E, 100% Effort) $1,000,000 (no indirect costs). 4/1/2012-4/1/2017. Funds to support the creation of a new independent laboratory at the University of Miami studying Hepatocellular Carcinoma and Viral Hepatitis.